Ascentage Pharma of Suzhou was granted Orphan Drug Designation in the US for a novel MDM2-p53 inhibitor as a treatment for gastric cancer. It is the first ODD for APG-115. Although GC is a rare disease in the US , it is the third leading cause of cancer deaths worldwide, with a very high incidence in China and Japan . Ascentage said APG-115 has shown promising results in preclinical GC tests. One week ago, Ascentage reported its novel Bcl-2 inhibitor was awarded ODD in the US for chronic lymphocytic leukemia. More details.... Stock Symbols: (HK: 6855) Share this with colleagues: // //